21 results
Search Results
Now showing 1 - 10 of 21
Publication Metadata only Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): An open-label, randomised trial(2010-11-13) Arjen M. Dondorp; Caterina I. Fanello; Ilse Ce Hendriksen; Ermelinda Gomes; Amir Seni; Kajal D. Chhaganlal; Kalifa Bojang; Rasaq Olaosebikan; Nkechinyere Anunobi; Kathryn Maitland; Esther Kivaya; Tsiri Agbenyega; Samuel Blay Nguah; Jennifer Evans; Samwel Gesase; Catherine Kahabuka; George Mtove; Behzad Nadjm; Jacqueline Deen; Juliet Mwanga-Amumpaire; Margaret Nansumba; Corine Karema; Noella Umulisa; Aline Uwimana; Olugbenga A. Mokuolu; Olanrewaju T. Adedoyin; Wahab Br Johnson; Antoinette K. Tshefu; Marie A. Onyamboko; Tharisara Sakulthaew; Wirichada Pan Ngum; Kamolrat Silamut; Kasia Stepniewska; Charles J. Woodrow; Delia Bethell; Bridget Wills; Martina Oneko; Tim E. Peto; Lorenz Von Seidlein; Nicholas Pj Day; Nicholas J. White; Hospital Central da Beira; Medical Research Council Laboratories Gambia; I/C Komfo Anokye Hosp.; Kilifi District Hospital; Magunga District Hospital; Teule Designated District Hospital; NIMR-Amani Centre; Ministry of Health; University of Ilorin; Mbarara University of Science and Technology; Kinshasa School of Public Health-Kingasani Research Centre; Mahidol University; Nuffield Department of Clinical Medicine; Menzies School of Health Research; Oxford University Clinical Research Unit; KEMRI-CDC Kisumu) with severe falciparum malaria were randomly assigned to parenteral artesunate or parenteral quinine. Randomisation was in blocks of 20, with study numbers corresponding to treatment allocations kept inside opaque sealed paper envelopes. The trial was open... is registered, number ISRCTN50258054. 5425 children were enrolled; 2712 were assigned to artesunate and 2713 to quinine. All patients were analysed for the primary outcome. 230 (8·5) patients assigned to artesunate treatment died compared with 297 (10·9Publication Metadata only Acetaminophen as a Renoprotective Adjunctive Treatment in Patients with Severe and Moderately Severe Falciparum Malaria: A Randomized, Controlled, Open-Label Trial(2018-09-14) Katherine Plewes; Hugh W.F. Kingston; Aniruddha Ghose; Thanaporn Wattanakul; Md Mahtab Uddin Hassan; Md Shafiul Haider; Prodip K. Dutta; Md Akhterul Islam; Shamsul Alam; Selim Md Jahangir; A. S.M. Zahed; Md Abdus Sattar; M. A.Hassan Chowdhury; M. Trent Herdman; Stije J. Leopold; Haruhiko Ishioka; Kim A. Piera; Prakaykaew Charunwatthana; Kamolrat Silamut; Tsin W. Yeo; Sue J. Lee; Mavuto Mukaka; Richard J. Maude; Gareth D.H. Turner; Md Abul Faiz; Joel Tarning; John A. Oates; Nicholas M. Anstey; Nicholas J. White; Nicholas P.J. Day; Md Amir Hossain; L. Jackson Roberts; Arjen M. Dondorp; Harvard School of Public Health; Menzies School of Health Research; Mahidol University; Chittagong Medical College Hospital; The University of British Columbia; Nuffield Department of Clinical Medicine; Vanderbilt University School of Medicine; Nanyang Technological University; Ramu Upazilla Health Complex; Dev Care Foundation) properties and pharmacodynamic (PD) effects of acetaminophen. Febrile patients (>12 years) with severe falciparum malaria were randomly assigned to receive acetaminophen (1 g 6-hourly for 72 hours) or no acetaminophen, in addition to intravenous artesunate.... Primary outcome was the proportional change in creatinine after 72 hours stratified by median plasma hemoglobin. Results Between 2012 and 2014, 62 patients were randomly assigned to receive acetaminophen (n = 31) or no acetaminophen (n = 31). MedianPublication Metadata only Trimethoprim/sulfamethoxazole resistance in clinical isolates of Burkholderia pseudomallei(2005-06-01) Vanaporn Wuthiekanun; Allen C. Cheng; Wirongrong Chierakul; Premjit Amornchai; Direk Limmathurotsakul; Wipada Chaowagul; Andrew J.H. Simpson; Jennifer M. Short; Gumphol Wongsuvan; Bina Maharjan; Nicholas J. White; Sharon J. Peacock; Mahidol University; Menzies School of Health Research; Sappasitthiprasong Hospital; Dstl; Heartlands Hospital; Nuffield Department of Clinical Medicineassigned as 'susceptible' or 'intermediate' by disc diffusion may be viewed as 'susceptible'; those assigned as 'resistant' require further evaluation by MIC methodology. © The Author 2005. Published by Oxford University Press on behalf of the BritishPublication Metadata only Efficacy and effectiveness of dihydroartemisinin-piperaquine versus artesunate-mefloquine in falciparum malaria: an open-label randomised comparison(2006-06-24) Frank Smithuis; Moe Kyaw Kyaw; Ohn Phe; Khin Zarli Aye; Lhin Htet; Marion Barends; Niklas Lindegardh; Thida Singtoroj; Elizabeth Ashley; Saw Lwin; Kasia Stepniewska; Nicholas J. White; Médecins Sans Frontières (Holland); Shoklo Malaria Research Unit; Mahidol University; Churchill Hospitalwith uncomplicated falciparum malaria in Rakhine State, western Myanmar. Within each group, patients were randomly assigned supervised or non-supervised treatment. The primary endpoint was the PCR-confirmed parasitological failure rate by day 42. Failure rates at day... 42 were estimated by Kaplan-Meier survival analysis. This study is registered as an International Standard Randomised Controlled Trial, number ISRCTN27914471. Findings: Of 652 patients enrolled, 327 were assigned dihydroartemisinin-piperaquine (156Publication Metadata only Triple artemisinin-based combination therapies versus artemisinin-based combination therapies for uncomplicated Plasmodium falciparum malaria: a multicentre, open-label, randomised clinical trial(2020-04-25) Rob W. van der Pluijm; Rupam Tripura; Richard M. Hoglund; Aung Pyae Phyo; Dysoley Lek; Akhter ul Islam; Anupkumar R. Anvikar; Parthasarathi Satpathi; Sanghamitra Satpathi; Prativa Kumari Behera; Amar Tripura; Subrata Baidya; Marie Onyamboko; Nguyen Hoang Chau; Yok Sovann; Seila Suon; Sokunthea Sreng; Sivanna Mao; Savuth Oun; Sovannary Yen; Chanaki Amaratunga; Kitipumi Chutasmit; Chalermpon Saelow; Ratchadaporn Runcharern; Weerayuth Kaewmok; Nhu Thi Hoa; Ngo Viet Thanh; Borimas Hanboonkunupakarn; James J. Callery; Akshaya Kumar Mohanty; James Heaton; Myo Thant; Kripasindhu Gantait; Tarapada Ghosh; Roberto Amato; Richard D. Pearson; Christopher G. Jacob; Sónia Gonçalves; Mavuto Mukaka; Naomi Waithira; Charles J. Woodrow; Martin P. Grobusch; Michele van Vugt; Rick M. Fairhurst; Phaik Yeong Cheah; Thomas J. Peto; Lorenz von Seidlein; Mehul Dhorda; Richard J. Maude; Markus Winterberg; Nguyen Thanh Thuy-Nhien; Dominic P. Kwiatkowski; Mallika Imwong; Podjanee Jittamala; Khin Lin; Tin Maung Hlaing; Kesinee Chotivanich; Rekol Huy; Caterina Fanello; Elizabeth Ashley; Mayfong Mayxay; Paul N. Newton; Tran Tinh Hien; Neena Valecha; Frank Smithuis; Sasithon Pukrittayakamee; Abul Faiz; Olivo Miotto; Joel Tarning; Nicholas P.J. Day; Nicholas J. White; Arjen M. Dondorp; Aung Pyae Phyo; Neena Valeche; Nicholas PJ Day; Oxford University Clinical Research Unit; Ispat General Hospital; Harvard T.H. Chan School of Public Health; University of Oxford; National Institute of Malaria Research India; National Institute of Allergy and Infectious Diseases; Mahosot Hospital, Lao; Mahidol University; Open University; Nuffield Department of Clinical Medicine; Wellcome Sanger Institute; AstraZeneca; Universiteit van Amsterdam; National Institute of Public Health; Pailin Provincial Health Department; Myanmar Oxford Clinical Research Unit; Kinshasa Mahidol Oxford Research Unit (KIMORU); Asia Regional Centre; Ramu Upazila Health Complex; Malaria Research Group and Dev Care Foundation; Defence Services Medical Academy; Khun Han Hospital; Phusing Hospital; Ratanakiri Referral Hospital; Sampov Meas Referral Hospital; Agartala Medical College; Royal Society of Thailand; Midnapore Medical College; National Centre for Parasitology, Entomology and Malaria Control; Kinshasa School of Public Health; University of Health Sciences; IGHor mixed with non-falciparum species, and a temperature of 37·5°C or higher, or a history of fever in the past 24 h. Patients were randomly assigned (1:1) to one of two treatments using block randomisation, depending on their location: in Thailand, Cambodia..., Vietnam, and Myanmar patients were assigned to either dihydroartemisinin–piperaquine or dihydroartemisinin–piperaquine plus mefloquine; at three sites in Cambodia they were assigned to either artesunate–mefloquine or dihydroartemisinin–piperaquine plusPublication Metadata only Single dose primaquine for clearance of Plasmodium falciparum gametocytes in children with uncomplicated malaria in Uganda: A randomised, controlled, double-blind, dose-ranging trial(2014-02-01) Alice C. Eziefula; Teun Bousema; Shunmay Yeung; Moses Kamya; Asiphas Owaraganise; Grace Gabagaya; John Bradley; Lynn Grignard; Kjerstin H.W. Lanke; Humphrey Wanzira; Arthur Mpimbaza; Samuel Nsobya; Nicholas J. White; Emily L. Webb; Sarah G. Staedke; Chris Drakeley; London School of Hygiene & Tropical Medicine; Radboud University Nijmegen Medical Centre; Infectious Diseases Research Collaboration; Makerere University; Mahidol University, combined with either placebo or with 0·1 mg/kg, 0·4 mg/kg, or 0·75 mg/kg (WHO reference dose) primaquine base. Randomisation was done with computer-generated four-digit treatment assignment codes allocated to random dose groups in block sizes of 16. Study... staff who provided care or assessed outcomes and the participants remained masked to the intervention group after assignment. The primary efficacy endpoint was the non-inferiority of the mean duration of gametocyte carriage in the test doses comparedPublication Metadata only Assessment of the neurotoxicity of parenteral artemisinin derivatives in mice(1998-01-01) Apichart Nontprasert; Marika Nosten-Bertrand; Sasithon Pukrittayakamee; Sirivan Vanijanonta; Brian J. Angus; Nicholas J. White; Mahidol University; Hopital Pitie Salpetriereof parenteral artesunate and artemether was compared in a murine model. Adult Swiss albino mice were assigned randomly to 28-day regimens of intramuscular artemether or artesunate in doses ranging from 30 to 100 mg/kg/day. At 30 mg/kg/day, no abnormalities werePublication Metadata only Arterolane–piperaquine–mefloquine versus arterolane–piperaquine and artemether–lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children: a single-centre, open-label, randomised, non-inferiority trial(2021-10-01) Mainga Hamaluba; Rob W. van der Pluijm; Joseph Weya; Patricia Njuguna; Mwanajuma Ngama; Peter Kalume; Gabriel Mwambingu; Caroline Ngetsa; Juliana Wambua; Mwanamvua Boga; Neema Mturi; Altaf A. Lal; Arshad Khuroo; Walter R.J. Taylor; Sónia Gonçalves; Olivo Miotto; Mehul Dhorda; Brian Mutinda; Mavuto Mukaka; Naomi Waithira; Richard M. Hoglund; Mallika Imwong; Joel Tarning; Nicholas P.J. Day; Nicholas J. White; Philip Bejon; Arjen M. Dondorp; Faculty of Tropical Medicine, Mahidol University; Wellcome Trust Research Laboratories Nairobi; Nuffield Department of Medicine; Wellcome Sanger Institute; Sun Pharmaceutical Industries Ltd.; Worldwide Antimalarial Resistance Networkor contraindication to any of the study drugs, and a QT interval corrected for heart rate (QTc interval) longer than 450 ms. Patients were randomly assigned (1:1:1), by use of blocks of six, nine, and 12, and opaque, sealed, and sequentially numbered envelopes... treatments was −7%. The study is registered in ClinicalTrials.gov, NCT03452475, and is completed. Findings: Between March 7, 2018, and May 2, 2019, 533 children with P falciparum were screened, of whom 217 were randomly assigned to receive either arterolanePublication Metadata only Treatment of uncomplicated multidrug-resistant falciparum malaria with artesunate-atovaquone-proguanil(2002-12-15) Michèle Van Vugt; Elisabetta Leonardi; Lucy Phaipun; Thra Slight; Kyaw Lay Thway; Rose McGready; Alan Brockman; Leopoldo Villegas; Sornchai Looareesuwan; Nicholas J. White; Franc̃ois Nosten; Shoklo Malaria Research Unit; Mahidol University; Slotervaart Hospital; John Radcliffe HospitalIn an open-label trial carried out on the northwest border of Thailand, 1596 patients with uncomplicated multidrug-resistant falciparum malaria were randomly assigned to receive atovaquone-proguanil, atovaquone-proguanil-artesunate, or artesunatePublication Metadata only Clinical trial of oral artesunate with or without high-dose primaquine for the treatment of vivax malaria in Thailand.(2003-07-01) Udomsak Silachamroon; Srivicha Krudsood; Sombat Treeprasertsuk; Polrat Wilairatana; Kobsiri Chalearmrult; Hla Yin Mint; Pannamas Maneekan; Nicholas J. White; Victor R. Gourdeuk; Gary M. Brittenham; Sornchai Looareesuwan; Mahidol University, and effectiveness of a high dose of primaquine in prevention of relapse. Patients were randomly assigned to one of four treatment groups: 1) a five-day course of artesunate (Group A5); 2) a seven-day course of artesunate (Group A7); 3) a five-day course
- «
- 1 (current)
- 2
- 3
- »